The current price of BSX is $44.26 — it has decreased by 3.40% since the previous close. Data as of Nov 5, 2026.
BSX is up 3.05% over the past week, up 4.39% over the past month and down 55.25% over the past year. The price is below its 200-day moving average of $55.84.
Analysts' average 12-month price target for BSX is $54.65, which implies 23.47% upside from the current price. Individual estimates range from $46.00 to $71.00.
Of the 31 analysts covering Boston Scientific Corporation, 6 rate it a strong buy, 14 rate it a buy and 11 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Boston Scientific Corporation has a market capitalization of $64.14B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Boston Scientific Corporation posted earnings of $0.73 per share against an estimate of $0.727, beating expectations by 0.41%. Upcoming reports are listed in the earnings calendar.
Boston Scientific Corporation reported revenue of $5.14B in its most recent quarter, which has increased by 1.44% compared with the same quarter a year earlier. Analysts had expected $5.09B.
Boston Scientific Corporation has not paid any dividends over the past year.
Companies most comparable to Boston Scientific Corporation include Medtronic Plc, Edwards Lifesciences Corporation, Penumbra, Inc., Teleflex Incorporated and Merit Medical Systems, Inc.
In the latest trading session BSX moved between $44.25 and $46.76, a range of 5.67% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Boston Scientific Corporation shows a neutral rating today. Technical ratings are indicators, not investment advice.
Over the past 52 weeks BSX has traded between $39.57 and $105.65. The current price is 58.11% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.